Tamar Thompson
Director/Board Member chez AVIDITY BIOSCIENCES, INC.
Fortune : - $ au 31/03/2024
Profil
Tamar Thompson is currently serving as the Chairman of the Alexion Charitable Foundation.
Additionally, Ms. Thompson holds the position of Independent Director at Catalyst Pharmaceuticals, Inc. since 2023, Independent Director at Avidity Biosciences, Inc. since 2021, and Vice President of US Government Affairs & Policy at Alexion Pharmaceuticals, Inc. since 2019.
Ms. Thompson previously worked at Bristol Myers Squibb Co. as the Head of Federal Executive Branch Strategy from 2015 to 2019.
Ms. Thompson obtained a graduate degree from Trident University International.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AVIDITY BIOSCIENCES INC
-.--% | 15/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Tamar Thompson
| Sociétés | Poste | Début |
|---|---|---|
| AVIDITY BIOSCIENCES, INC. | Director/Board Member | 11/01/2021 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/11/2019 |
| CATALYST PHARMACEUTICALS, INC. | Director/Board Member | 25/05/2023 |
| Alexion Charitable Foundation | Chairman | - |
Anciens postes connus de Tamar Thompson
| Sociétés | Poste | Fin |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/11/2019 |
Formation de Tamar Thompson
| Trident University International | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| CATALYST PHARMACEUTICALS, INC. | Health Technology |
| AVIDITY BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
| Alexion Charitable Foundation |
